Mirum Pharmaceuticals at Stifel 2026 Healthcare Conference: growth broadens
At a glance
- $MIRM today+0.50%last $92.04
- Vs industry peers+1.16 pts6-peer median −0.65% · ahead
- Since Nov 11−2.66%from the first trade after the story
- 52-week range45.6% above low$63.23 – $130.00
- Cash runway~8 mo$243.2M cash ÷ $30.9M/mo burn · 10-Q
- Coverage10 this week21 in 30 days · 2.0× its usual pace
Nothing reported about mirum pharmaceuticals across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Good trial results are only step one; approval timing and pricing decide how much it is worth.
- How the stocks are trading: $MIRM +0.50%, $SF -1.82%, $HR -1.16% in the latest session.
- Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Where the stock stands
Mirum Pharmaceuticals ($MIRM) ticked up 0.50% to $92.04 in the latest session. Over the past month it is up 11.9%. It now sits 29% under the 52-week high of $130.00 and 46% above the year's low of $63.23. The year's high was 2.1 times its low, which makes double-digit swings fairly routine here. Stifel Financial ($SF) fell 1.82% to $71.27 in the latest session. Over the past month it is up 7.9%. That leaves it 21% below its 52-week high of $89.83 and 9.0% above its low of $65.40. The high sits 37% above the low, a moderate range for a year.
What the filings say
In its latest report (10-Q, filed Nov 3, 2026), $MIRM lost $40.8M over the quarter to Sep 30, 2026 on revenue of $185.7M (+5.4% QoQ). Operations used $277.3M of cash over the nine months to Sep 30, 2026 — about $30.9M a month — against $243.2M in cash on Sep 30, 2026. At that pace the cash covers about 8 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $1.08B against $243.2M of cash on Sep 30, 2026. Liabilities of $1.08B exceeded assets of $1.03B on Sep 30, 2026, leaving book equity negative. The company filed an 8-K — the form for material events — on Nov 10, 1 day before this story; it is $MIRM's own account and the first thing to read. Figures are as filed with the SEC; the $MIRM page has the full statements.
How much coverage it is getting
Wook has filed 21 stories on these companies in the last 30 days, 10 of them this week. Its 30-day average is about 5 a week, so this week is running well ahead of normal. Going by their wording, 24% read bullish, 76% neutral and 0% bearish. This one reads bullish, which puts it against most of that coverage. Investing.com wrote 12 of the 21 (57%), so the count reflects one outlet's output more than broad attention.
The bigger picture
In healthcare, a single FDA decision or trial update can shift a drugmaker's fate, while pricing changes ripple across the whole sector. Wook's supply-chain scanner shows no unusual stress in Health Care today.
What to watch next
The $MIRM page has all the charts, filings, and models. Comparing coverage from different outlets helps spot confirmation or repetition. Wook AI can pull live data and run the numbers on request.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 11, 2026. $MIRM has moved -2.66% ($94.56 to $92.04), $SF has moved -2.40% ($73.02 to $71.27) and $HR has moved -0.55% ($19.20 to $19.09). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
